Milsaperidone

  1. Home
  2. Wiki

Milsaperidone
Clinical data
Trade namesBysanti
Other namesVHX896
Routes of
administration		Oral
Drug classAtypical antipsychotic
Identifiers
  • (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC24H29FN2O4
Molar mass428.504 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC)O
  • InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3/t16-/m0/s1
  • Key:SBKZGLWZGZQVHA-INIZCTEOSA-N

Milsaperidone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name VHX-896 and its tentative brand name Bysanti, is an atypical antipsychotic which is pending approval for the treatment of schizophrenia and bipolar disorder and is in phase 3 clinical trials for treatment of major depressive disorder.[1][2][3] It is a prodrug of iloperidone (Fanapt) and acts as a dopamine D2 receptor and serotonin 5-HT2A receptor antagonist, among other actions.[1][4][5] The drug was developed by Vanda Pharmaceuticals.[1]

See also

[edit]

References

[edit]
  1. ^ a b c "Vanda Pharmaceuticals". AdisInsight. 30 July 2025. Retrieved 11 October 2025.
  2. ^ IsHak WW, Hirsch D, Renteria S, Totlani J, Murphy N, Chang T, et al. (October 2025). "Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications". BMC Psychiatry. 25 (1) 939. doi:10.1186/s12888-025-07141-3. PMC 12506068. PMID 41057811.
  3. ^ Richmond LM (1 June 2025). "Med Check: FDA Accepts Bysanti Application, Cobenfy Fails as Adjunct, and More". Psychiatric News. 60 (6) appi.pn.2025.06.6.2. doi:10.1176/appi.pn.2025.06.6.2. ISSN 0033-2704. Retrieved 11 October 2025.
  4. ^ Kang J (9 May 2025). "Milsaperidone Under Review for Bipolar I Disorder and Schizophrenia". MPR. Retrieved 11 October 2025.
  5. ^ "Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026". BioSpace. 5 May 2025. Retrieved 11 October 2025.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.